Anguizole
(Synonyms: 7-(氯二氟甲基)-5-(2-呋喃基)-N-(2-噻吩基甲基)吡唑并[1,5-A]嘧啶-2-甲酰胺,7-[chloro(difluoro)methyl]-5-(furan-2-yl)-N-(thiophen-2-ylmethyl)pyrazolo[1,5-a]pyrimidine-2-carboxamide) 目录号 : GC14937Anguizole 是一种 HCV 复制的小分子抑制剂,可改变 NS4B 的亚细胞分布。
Cas No.:442666-98-0
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Anguizole is a selective inhibitor of NS4B with IC50 value of 310 nM [1].
NS4B (nonstructural protein 4B) is a viral protein which was found in hepatitis C virus and was a key regulator in HCV replication complex formation. It is reported that NS4B plays a pivotal role in HCV replication via inducing a specific membrane rearrangement and designating membranous web. NS4B-AH2, comprising amino acid 42 to 66, is identified as a major regulator for NS4B oligomerization [2].
Anguizole is a potent NS4B inhibitor and targets the second amphipathic helix of NS4B (NS4B-AH2). When tested with HCV virus, anguizole treatment significantly disrupted NS4B-AH2-mediated biological functions of NS4B which played an important role in HCV life cycle [3]. In Huh7.5 cells transferring a plasmid expressing NS4B fused in frame with GFP, 5μM anguizole treatment (48 hours) altered the distribution of NS4B MAF pattern which inhibited HCV life cycle [1].
References:
[1]. Bryson, P.D., et al., A small molecule inhibits HCV replication and alters NS4B's subcellular distribution. Antiviral Res, 2010. 87(1): p. 1-8.
[2]. Gouttenoire, J., et al., Aminoterminal amphipathic alpha-helix AH1 of hepatitis C virus nonstructural protein 4B possesses a dual role in RNA replication and virus production. PLoS Pathog, 2014. 10(10): p. e1004501.
[3]. Choi, M., et al., A hepatitis C virus NS4B inhibitor suppresses viral genome replication by disrupting NS4B's dimerization/multimerization as well as its interaction with NS5A. Virus Genes, 2013. 47(3): p. 395-407.
Cas No. | 442666-98-0 | SDF | |
别名 | 7-(氯二氟甲基)-5-(2-呋喃基)-N-(2-噻吩基甲基)吡唑并[1,5-A]嘧啶-2-甲酰胺,7-[chloro(difluoro)methyl]-5-(furan-2-yl)-N-(thiophen-2-ylmethyl)pyrazolo[1,5-a]pyrimidine-2-carboxamide | ||
化学名 | 7-[chloro(difluoro)methyl]-5-(furan-2-yl)-N-(thiophen-2-ylmethyl)pyrazolo[1,5-a]pyrimidine-2-carboxamide | ||
Canonical SMILES | C1=COC(=C1)C2=NC3=CC(=NN3C(=C2)C(F)(F)Cl)C(=O)NCC4=CC=CS4 | ||
分子式 | C17H11ClF2N4O2S | 分子量 | 408.81 |
溶解度 | DMSO : 50 mg/mL (122.31 mM; Need ultrasonic) | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.4461 mL | 12.2306 mL | 24.4612 mL |
5 mM | 0.4892 mL | 2.4461 mL | 4.8922 mL |
10 mM | 0.2446 mL | 1.2231 mL | 2.4461 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。